IL286818B2 - Mirikizumab for use in the treatment of Crohn's disease - Google Patents

Mirikizumab for use in the treatment of Crohn's disease

Info

Publication number
IL286818B2
IL286818B2 IL286818A IL28681821A IL286818B2 IL 286818 B2 IL286818 B2 IL 286818B2 IL 286818 A IL286818 A IL 286818A IL 28681821 A IL28681821 A IL 28681821A IL 286818 B2 IL286818 B2 IL 286818B2
Authority
IL
Israel
Prior art keywords
mirikizumab
administered
weeks
dose
endoscopic
Prior art date
Application number
IL286818A
Other languages
English (en)
Hebrew (he)
Other versions
IL286818A (en
IL286818B1 (en
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL286818A publication Critical patent/IL286818A/en
Publication of IL286818B1 publication Critical patent/IL286818B1/en
Publication of IL286818B2 publication Critical patent/IL286818B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
IL286818A 2019-04-22 2020-04-15 Mirikizumab for use in the treatment of Crohn's disease IL286818B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962836910P 2019-04-22 2019-04-22
PCT/US2020/028273 WO2020219314A1 (en) 2019-04-22 2020-04-15 Mirikizumab for use in a method of treating crohn's disease

Publications (3)

Publication Number Publication Date
IL286818A IL286818A (en) 2021-10-31
IL286818B1 IL286818B1 (en) 2025-11-01
IL286818B2 true IL286818B2 (en) 2026-03-01

Family

ID=70554215

Family Applications (2)

Application Number Title Priority Date Filing Date
IL286818A IL286818B2 (en) 2019-04-22 2020-04-15 Mirikizumab for use in the treatment of Crohn's disease
IL324048A IL324048A (en) 2019-04-22 2025-10-19 Mirikizumab for use in a method of treating crohn's disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL324048A IL324048A (en) 2019-04-22 2025-10-19 Mirikizumab for use in a method of treating crohn's disease

Country Status (21)

Country Link
US (1) US20220040299A1 (enExample)
EP (3) EP3958897B1 (enExample)
JP (3) JP7297930B2 (enExample)
KR (2) KR20250153865A (enExample)
CN (2) CN119700968A (enExample)
AU (2) AU2020263238C1 (enExample)
BR (1) BR112021018930A2 (enExample)
DK (1) DK3958897T3 (enExample)
EA (1) EA202192532A1 (enExample)
ES (1) ES3075314T3 (enExample)
FI (1) FI3958897T3 (enExample)
IL (2) IL286818B2 (enExample)
LT (1) LT3958897T (enExample)
MA (1) MA55756A (enExample)
MX (1) MX2021012848A (enExample)
PT (1) PT3958897T (enExample)
SG (1) SG11202110619XA (enExample)
TW (2) TWI850365B (enExample)
UA (1) UA128657C2 (enExample)
WO (1) WO2020219314A1 (enExample)
ZA (1) ZA202108094B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI850365B (zh) * 2019-04-22 2024-08-01 美商美國禮來大藥廠 治療克隆氏症(crohn's disease)的方法
KR20220066831A (ko) 2020-11-16 2022-05-24 엔브이에이치코리아(주) 습기경화형 접착제를 이용한 헤드라이닝 제조방법 및 이에 의해 제조되는 헤드라이닝

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017048901A1 (en) * 2015-09-18 2017-03-23 Boehringer Ingelheim International Gmbh Methods of treating inflammatory diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20140049B1 (ar) 2013-03-08 2021-08-17 Lilly Co Eli أجسام مضادة ترتبط بـ il-23
US20160031983A1 (en) 2013-03-15 2016-02-04 Amgen Inc. Methods for treating crohn's disease using an anti-il23 antibody
WO2018035330A1 (en) * 2016-08-19 2018-02-22 Janssen Biotech, Inc. Methods of treating crohn's disease with an anti-nkg2d antibody
EP3652539A4 (en) * 2017-07-10 2021-03-31 Rambam Med-Tech Ltd. ASSAYS FOR EVALUATING NEUTRALIZING ANTIBODIES IN ORGANIC MEDICINE TREATED PATIENTS AND USES THEREOF IN PERSONALIZED MEDICINE
TWI850365B (zh) * 2019-04-22 2024-08-01 美商美國禮來大藥廠 治療克隆氏症(crohn's disease)的方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017048901A1 (en) * 2015-09-18 2017-03-23 Boehringer Ingelheim International Gmbh Methods of treating inflammatory diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHRISTOPHER MA ET AL,, INVESTIGATIONAL DRUGS IN PHASE I AND PHASE II CLINICAL TRIALS TARGETING INTERLEUKIN 23 (IL23) FOR THE TREATMENT OF CROHN'S DISEASE, 3 August 2018 (2018-08-03) *

Also Published As

Publication number Publication date
CN113677366A (zh) 2021-11-19
BR112021018930A2 (pt) 2022-01-18
EP3958897A1 (en) 2022-03-02
JP7761614B2 (ja) 2025-10-28
ZA202108094B (en) 2025-05-28
TW202515610A (zh) 2025-04-16
AU2020263238B2 (en) 2023-08-17
AU2020263238C1 (en) 2024-02-22
WO2020219314A1 (en) 2020-10-29
EP4778573A2 (en) 2026-07-22
TWI850365B (zh) 2024-08-01
CN119700968A (zh) 2025-03-28
EP3958897B1 (en) 2026-05-06
PT3958897T (pt) 2026-07-17
KR20250153865A (ko) 2025-10-27
AU2020263238A1 (en) 2021-11-04
SG11202110619XA (en) 2021-11-29
IL286818A (en) 2021-10-31
EA202192532A1 (ru) 2022-01-21
JP2025148449A (ja) 2025-10-07
EP4789714A2 (en) 2026-08-12
UA128657C2 (uk) 2024-09-18
KR102869852B1 (ko) 2025-10-14
NZ781127A (en) 2025-06-27
MX2021012848A (es) 2021-12-10
DK3958897T3 (da) 2026-07-20
JP7297930B2 (ja) 2023-06-26
US20220040299A1 (en) 2022-02-10
TW202103734A (zh) 2021-02-01
LT3958897T (lt) 2026-08-10
AU2023265759A1 (en) 2023-12-07
JP2023116680A (ja) 2023-08-22
ES3075314T3 (en) 2026-08-03
FI3958897T3 (fi) 2026-07-16
IL286818B1 (en) 2025-11-01
KR20210142704A (ko) 2021-11-25
MA55756A (fr) 2022-03-02
JP2022530397A (ja) 2022-06-29
CA3134587A1 (en) 2020-10-29
IL324048A (en) 2025-12-01

Similar Documents

Publication Publication Date Title
IL254768A0 (en) Method and device for treating vascular disease
ZA202007949B (en) Bone trabecula structure and prosthesis using same and manufacturing method therefor
EP3334372C0 (de) Verfahren zum herstellen eines anatomischen zahnimplantats
SG11202106794WA (en) Method for treating lower back pain
GB2573257B (en) Method and machine for producing titanium cobbles
ES3065184T3 (en) Use of migalastat for treating fabry disease in pregnant patients
PT3600415T (pt) Anticorpo contra recetor de activina do recetor do tipo ii para utilização no tratamento de insuficiência cardíaca
GB2525023B (en) Apparatus and method for treating a patient having a heart
EP3275471A4 (en) Three-dimensional structure for cardiac muscular tissue regeneration and manufacturing method therefor
IL289309A (en) Methods and materials for treating Huntington's disease
IL289273A (en) Plant disease control agent and plant disease control method
ZA202107235B (en) Compositions and methods for treating ocular disease
ZA202005720B (en) Method for treating asthma or allergic disease
ZA201800632B (en) Method for treating diseases in plants
EP3936633C0 (en) PROCESSING METHOD FOR ZIRCONIUM ALLOY AND APPLICATION
IL284629A (en) Methods for treating eye surface pain
GB2568032B (en) A method of production of phytocannabinoids for use in medical treatments
IL276639A (en) Materials and methods for the treatment of dysproliferative diseases
ZA202001927B (en) Method for treating tnf alpha-related diseases
IL290770A (en) Compounds and methods for treating oxalate-related diseases
SG11202110619XA (en) Mirikizumab for use in a method of treating crohn's disease
ZA201805679B (en) Method and composition for treating cancer or skin lesion using a vaccine
SI4072532T1 (sl) Dozirna oblika za uporabo v zdravljenju ali preprečevanju bolezni
HUE062624T2 (hu) Mechanikus felületkezelõ szerszám és eljárás
PL3812851T3 (pl) Sposób i układ do ustawiania parametrów cyklu działania